Santa Clarita, CANCT06880770Now EnrollingIRB Ready

Severe Hypertriglyceridemia Clinical Trial in Santa Clarita, CA

Access cutting-edge severe hypertriglyceridemia treatment through this phase 3 clinical trial at a research site in Santa Clarita. Study-provided care at no cost to qualified participants.

Sponsored by Arrowhead Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Santa Clarita location

Preparing your pre-screening questions…

Expert Care in Santa Clarita

Access severe hypertriglyceridemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related severe hypertriglyceridemia treatment provided free

Apply for This Santa Clarita Location

Check if you qualify for this severe hypertriglyceridemia clinical trial in Santa Clarita, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Santa Clarita

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Santa Clarita site if eligible
  4. 4Begin participation

About This Severe Hypertriglyceridemia Study in Santa Clarita

This study will evaluate the efficacy and safety of plozasiran in approximately 140 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months prior to screening. Eligible participants will be randomly assigned in a double-blind manner to either receive plozasiran 25 mg by subcutaneous (SC) injection every three months (Q3M) or matching placeb

Sponsor: Arrowhead Pharmaceuticals

Who Can Participate

Inclusion Criteria

Males, or nonpregnant (who do not plan to become pregnant) nonlactating females
Established diagnosis of SHTG and prior documented evidence of fasting TG levels of ≥ 880 mg/dL (≥ 10 mmol/L)
Documented evidence of at least 1 prior AP event not attributed to other etiologies occurring within the last 60 months prior to Screening.
Fasting low-density lipoprotein cholesterol (LDL-C) ≤ 130 mg/dL (≤ 3.37 mmol/L) at Screening
Screening hemoglobin A1c (HbA1c) ≤ 9.5%
Willing to follow diet counseling and maintain a stable low-fat diet
Must be on standard of care lipid and TG-lowering medications per local guidelines (unless documented as intolerant, or a treatment failure as determined by the Investigator)

Exclusion Criteria

Use of any hepatocyte-targeted small interfering ribonucleic acid (siRNA) that targets lipids and/or triglycerides within 365 days before Day 1, except inclisiran.
Use of any other hepatocyte targeted siRNA or antisense oligonucleotide molecule within 60 days or within 5 half-lives lives before day 1. Whichever is longer.
AP ≤ 4 weeks prior to Randomization/Day 1
Body mass index (BMI) \> 45 kg/m\^2
Any planned bariatric surgery or similar procedures to induce weight lost starting at consent through End of Study (EOS)
Planned coronary intervention (e.g. stent placement or heart bypass) during the study
History of arterial revascularization within 16 weeks of Screening
History of acute coronary syndrome event within 24 weeks of Screening
Recent atherosclerotic cardiovascular disease (ASCVD) event within 24 weeks of Screening
Recent unstable or symptomatic cardiac arrhythmia (including any associated medication changes) within 90 days of Screening. Individuals with stable well-controlled atrial arrhythmia will be allowed to participate in the study
History of pacemaker or automatic implantable cardioverter defibrillators implant within 30 days before Screening
New York Heart Association Class III-IV heart failure or last known ejection fraction of \< 30%
Current diagnosis of nephrotic syndrome
Chronic kidney disease, defined by an estimated glomerular filtration rate (eGFR) \< 20 mL/min/1.73 m\^2
Liver disease defined as cirrhosis or Child-Pugh Class B and C, or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5× Upper Limit of Normal (ULN) at Screening Note: Additional Inclusion/Exclusion Criteria may apply per protocol

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Santa Clarita?

Yes, this clinical trial (NCT06880770) has an active research site in Santa Clarita, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Severe Hypertriglyceridemia Treatment Options in Santa Clarita, CA

If you're searching for severe hypertriglyceridemia treatment options in Santa Clarita, CA, this clinical trial (NCT06880770) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Santa Clarita research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced severe hypertriglyceridemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all severe hypertriglyceridemia clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Santa Clarita, CA

See all heart attack clinical trials recruiting in Santa Clarita — not just this study.

Browse Heart Attack Trials in Santa Clarita →

Browse More Trials by Condition

Heart Attack TrialsPulmonary Embolism TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Santa Clarita?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Santa Clarita, CA